RT Journal Article
SR Electronic
T1 Cell-Free Tumor DNA Dominant Clone Allele Frequency (DCAF) Is Associated With Poor Outcomes In Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.01.21265773
DO 10.1101/2021.11.01.21265773
A1 Uson Junior, Pedro Luiz Serrano
A1 Majeed, Umair
A1 Yin, Jun
A1 Botrus, Gehan
A1 Sonbol, Mohamad Bassam
A1 Ahn, Daniel H.
A1 Starr, Jason S.
A1 Jones, Jeremy C
A1 Babiker, Hani
A1 Inabinett, Samantha R
A1 Wylie, Natasha
A1 Boyle, Ashton WR
A1 Bekaii-Saab, Tanios S.
A1 Gores, Gregory J
A1 Smoot, Rory
A1 Barrett, Michael
A1 Nagalo, Bolni
A1 Meurice, Nathalie
A1 Elliott, Natalie
A1 Petit, Joachim
A1 Zhou, Yumei
A1 Arora, Mansi
A1 Dumbauld, Chelsae
A1 Barro, Oumar
A1 Baker, Alexander
A1 Bogenberger, James
A1 Buetow, Kenneth
A1 Mansfield, Aaron
A1 Mody, Kabir
A1 Borad, Mitesh J.
YR 2021
UL http://medrxiv.org/content/early/2021/11/02/2021.11.01.21265773.abstract
AB PURPOSE This investigation sough to evaluate the prognostic value of pre-treatment ctDNA in metastatic biliary tract cancers (BTC) treated with platinum based first-line chemotherapy treatment.METHODS We performed a retrospective analysis of 67 patients who underwent ctDNA testing before platinum-based chemotherapy for first-line treatment for metastatic BTC. For analysis we considered the detected gene with highest variant allele frequency (VAF) as the dominant clone allele frequency (DCAF). Results of ctDNA analysis were correlated with patients’ demographics, progression-free survival (PFS) and overall survival (OS).RESULTS The median age of patients was 67 years (27-90). 54 (80.6%) of 67 patients evaluated had intrahepatic cholangiocarcinoma; seven had extrahepatic cholangiocarcinoma and six gallbladder cancers. 46 (68.6%) of the patients were treated with cisplatin plus gemcitabine, 16.4% of patients received gemcitabine and other platinum (carboplatin or oxaliplatin) combinations while 15% of patients were treated on a clinical trial with gemcitabine and cisplatin plus additional agents (CX4945, PEGPH20 or nab-paclitaxel). TP53, KRAS, FGFR2, ARID1A, STK11 and IDH1 were the genes with highest frequency as DCAF. Median DCAF was 3% (0-97%). DCAF >3% was associated with worse OS (median OS: 10.8 vs. 18.8 months, p=0.032). Stratifying DCAF in quartiles, DCAF>10% was significantly related to worse PFS (median PFS: 3 months, p=0.014) and worse OS (median OS: 7.0 months, p=0.001). Each 1% increase in ctDNA was associated with a hazard ratio of 13.1 in OS when adjusting for subtypes, metastatic sites, size of largest tumor, age, sex, and CA19-9.CONCLUSION DCAF at diagnosis of advanced BTC can stratify patients who have worse outcomes when treated with upfront platinum-based chemotherapy. Each increase in %ctDNA decrease survival probabilities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Mayo Clinic Hepatobiliary SPORE (P50CA 210964) funded the statistical analysis for this project. This work was supported by the National Institute of Health (NIH) through a DP2 Award CA195764 (to MJB); National Cancer Institute (NCI) K12 award CA090628 (to MJB), K01 award CA234324 (to BN), SPORE Project Award 5P50CA210964-03 (to GJG and MJB), SPORE Supplement Award 3P50CA210964-02S1 (to OB), Mayo Clinic Center for Individualized Medicine (CIM) Precision Cancer Therapeutics Program; and Mayo Clinic Cancer Center. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIHAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Mayo Clinic gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors